Reduce Sedentary Time (ReSeT) in Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL) Clinical Trial

Official title:

ReSeT in ALL: A Randomized Controlled Pilot Trial Testing a Multi-component Mobile Health Intervention to Reduce Sedentary Time in Adolescents With ALL During Maintenance Therapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06182163
• Other study ID #: APP-23-06044
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 5, 2024
• Est. completion date: November 4, 2024

Study information

• Verified date: December 2023
• Source: Children's Hospital Los Angeles
• Contact: Brittany J Van Remortel, MD, MPH
• Phone: 323-376-1067
• Email: bvanremortel[@]chla.usc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomized clinical trial is to test if a mobile health intervention, including a wearable fitness tracker with reminders to move, individualized coaching sessions, and an app-based peer support group, can decrease sedentary time (time spent sitting/lying down and inactive) in adolescents with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy. The main questions it aims to answer are:

• Is the intervention a feasible and acceptable way to decrease sedentary time among adolescents with ALL?

• Does the intervention show evidence that it may decrease sedentary time, increase quality of life, and improve blood glucose control and inflammation?

Participants in the intervention group will use their fitness tracker with reminders to move as well as support from other intervention participants and coaching with study staff to gradually decrease their sedentary time over 10 weeks. Researchers will compare the intervention group to a control group that receives education only to see if the intervention may be helpful to decrease sedentary time in adolescents with ALL. All participants will wear an activity tracker on the thigh for 7 days at the beginning and end of the study as well as complete quality of life questionnaires. Study labs will be collected three times (monthly) over the course of the 12-week study. All in-person study visits and labs will occur in conjunction with Oncology clinic visits for maintenance chemotherapy.

Description:

Sedentary behaviors are highly prevalent among adolescents with acute lymphoblastic leukemia (ALL) and may worsen the cardiometabolic effects and deconditioning commonly associated with therapy. Replacing sedentary time (ST) with short bouts of light activity has been shown to reduce adiposity and improve glucose metabolism. This randomized, controlled pilot trial tests the feasibility and acceptability of a 10-week, multi-component mobile health ST intervention in adolescents with ALL and will inform future larger studies. Thirty participants will be enrolled and randomized to the intervention or control group. The intervention group will receive a wearable fitness tracker with prompts to move and participate in an app-based peer support group and individualized coaching sessions. The control group will receive educational materials only. Primary endpoints are intervention feasibility and acceptability. As secondary endpoints, this trial will also evaluate trends of efficacy of the intervention to: 1)reduce device-measured and self-reported ST, 2)improve short-term glucose metabolism and inflammation, and 3) improve health-related quality of life and fatigue among intervention versus control participants. Feasibility will be measured by recruitment rate, fitness tracker wear time, and retention rate; acceptability will be measured quantitatively via study exit surveys and qualitatively among intervention participants with exit interviews. Interim analysis will be completed once half of the enrollment goal has been reached (15) in order to inform future study, and final analysis will be completed once all 30 participants have completed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: November 4, 2024
• Est. primary completion date: November 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 18 Years

Eligibility

Inclusion Criteria:

• 12-18 years of age at time of enrollment

• Has completed at least one cycle (3 months) of maintenance chemotherapy and have at least once cycle (3 months) remaining

• Baseline sedentary lifestyle with a self-reported average of 8 or more hours per day spent sedentary

• Are willing to reduce their sedentary time

• Parent/legal guardian available for consent (if applicable), and patient available for assent or consent as applicable

• Has access to internet and smartphone compatible with Fitbit and WhatsApp (own or parent/legal guardian's)

• Ability to participate in two virtual coaching sessions with study staff

• Fluent in English (Parent/legal guardian does not need to be fluent in English as long as they can provide consent, if needed, in their primary language)

Exclusion Criteria:

• No evidence of recurrent or metastatic disease

• Inability to obtain consent/assent

• Medical contraindication to daily standing and light physical activity (>1.5 METs)

• Intellectual disability or developmental delay which limits ability to fully participate in the study intervention

• No underlying diagnosis of diabetes mellitus

• No underlying diagnosis of an autoinflammatory/autoimmune or rheumatologic disorder

• Unable to obtain laboratory studies

• Unable to accurately perform quality of life surveys independently

• Unable to complete study-related surveys

• Pregnancy or current imprisonment

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia (ALL)
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Behavioral:
• Sedentary time intervention
Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital Los Angeles

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants enrolled at 6 months	Recruitment rate will serve as one of the primary markers of study feasibility to inform future trials. Number of participants recruited per week will be tracked to calculate the total participants enrolled at 6 months.	6 months
Primary	Number of participants who have completed all baseline and exit questionnaires at 12 weeks	Retention rate will also be a defining measure of study feasibility. Number of participants who complete all questionnaires at baseline and 12 weeks will be divided by the total number of participants to determine the retention rate.	12 weeks
Primary	Average intervention participant fitness tracker wear time over 10 weeks	Fitness tracker (Fitbit) wear time for each participant will be measured by the number of hours per day with detectable heart rate measurement. Total hours of fitness tracker wear time will be divided by total number of intervention days to calculate average daily wear time.	10 weeks
Primary	Participant satisfaction with the sedentary time intervention at 12 weeks	Participant acceptability of the sedentary time intervention will be assessed via exit surveys and semi-structured qualitative interviews with study participants at the end of the 12-week study period. The exit survey will assess participants' opinions on the perceived effectiveness of the intervention overall, as well as each intervention component (Fitbit with reminders to move, coaching sessions, app-based per support group), via Likert-scale questions.	12 weeks
Secondary	Change in average minutes per day of sedentary time from baseline to 12 weeks	Sedentary time will be measured using an activity monitor applied to the right thigh (ActivPAL accelerometer) that tracks how much time someone spends in low-intensity activities done while sitting or lying down (sedentary behaviors) over a 7-day period. Total minutes of sedentary time acquired will be divided by the number of valid accelerometer wear days to calculate the average minutes of sedentary time per day, which will be compared from baseline to post-intervention.	12 Weeks
Secondary	Change in average hours per day of uninterrupted sedentary time from baseline to 12 weeks	For all participants, sedentary time will be measured using an activity monitor applied to the right thigh (ActivPAL accelerometer) that tracks how much time someone spends in low-intensity activities done while sitting or lying down (sedentary behaviors) over a 7-day period. An uninterrupted sedentary hour will be defined as an hour with <250 steps. Total hours of uninterrupted sedentary time acquired will be divided by valid accelerometer wear days to calculate the average hours of uninterrupted sedentary time per day, which will be compared from baseline to post-intervention.	12 Weeks
Secondary	Change in hemoglobinA1c level from baseline to 12 weeks	A non-fasting blood sample (up to 2 mLs) will be collected via venipuncture or central line access along with clinically required labs at baseline (Week 0) and post-intervention (Week 12) for measurement of hemoglobin A1c, which provides an average of blood glucose trends over the past 2-3 months.	12 weeks
Secondary	Change in fructosamine level from baseline to 4 weeks	A non-fasting blood sample (up to 2 mLs) will be collected via venipuncture or central line access along with clinically required labs at baseline (Week 0), Week 4, and post-intervention (Week 12) for measurement of fructosamine, which provides an average of blood glucose trends over the past 2-4 weeks. Fructosamine level at 4 weeks will be compared to the baseline level.	4 weeks
Secondary	Change in fructosamine level from baseline to 12 weeks	A non-fasting blood sample (up to 2 mLs) will be collected via venipuncture or central line access along with clinically required labs at baseline (Week 0), Week 4, and post-intervention (Week 12) for measurement of fructosamine, which provides an average of blood glucose trends over the past 2-4 weeks. Fructosamine level at 12 weeks will be compared to the baseline level.	12 weeks
Secondary	Change in C-reactive protein (CRP) level from baseline to 4 weeks	A non-fasting blood sample (up to 1 mLs) will be collected via venipuncture or central line access along with clinically required labs at baseline (Week 0), Week 4, and post-intervention (Week 12) for measurement of CRP, which is a general marker of bodily inflammation. CRP level at 4 weeks will be compared to the baseline level.	4 weeks
Secondary	Change in C-reactive protein (CRP) level from baseline to 12 weeks	A non-fasting blood sample (up to 1 mLs) will be collected via venipuncture or central line access along with clinically required labs at baseline (Week 0), Week 4, and post-intervention (Week 12) for measurement of CRP, which is a general marker of bodily inflammation. CRP level at 12 weeks will be compared to the baseline level.	12 weeks
Secondary	Change in self-reported health-related quality of life (HRQOL) from baseline to 12 Weeks	Self-reported HRQOL will be measured with the 23-item Pediatric Quality of Life inventory (PedsQL) 4.0 Generic Core Scales (physical functioning, emotional functioning, social functioning, and school functioning) and 27-item PedsQL 3.0 Cancer Module (pain and hurt, nausea, procedural anxiety, treatment anxiety, worry, cognitive problems, perceived physical appearance, and communication). Items are reversed scored and linearly transformed on a scale from 0 to 100, with higher scores indicating better HRQOL and fewer problems or symptoms. Participant's scores at 12 weeks will be compared to the baseline score.	12 weeks
Secondary	Change in self-reported fatigue from baseline to 12 Weeks	Self-reported fatigue will be measured with the 18-item Pediatric Quality of Life inventory (PedsQL) 3.0 Multidimensional Fatigue Scale (general fatigue, sleep/rest fatigue, cognitive fatigue). Items are reversed scored and linearly transformed on a scale from 0 to 100, with higher scores indicating better HRQOL and fewer problems or symptoms. Participant's scores at 12 weeks will be compared to the baseline score.	12 weeks